Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile-Reference-Cited by-同舟云学术

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile

Published:2018-04-03 Issue:25 Volume:9 Page:17270-17281
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Reidel Veronika¹,Kauschinger Johanna¹,Hauch Richard T.¹,Müller-Thomas Catharina¹,Nadarajah Niroshan²,Burgkart Rainer³,Schmidt Burkhard⁴,Hempel Dirk⁵,Jacob Anne¹,Slotta-Huspenina Julia⁶,Höckendorf Ulrike¹,Peschel Christian¹⁷,Kern Wolfgang²,Haferlach Torsten²,Götze Katharina S.¹⁷,Jilg Stefanie¹,Jost Philipp J.¹⁷

Affiliation:

1. Medizinische Klinik für Hämatologie und Internistische Onkologie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

2. Munich Leukemia Laboratory (MLL), Munich, Germany

3. Klinik für Orthopädie und Sportorthopädie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

4. Gemeinschaftspraxis Hämato-Onkologie Pasing, Munich, Germany

5. Onkologisches Zentrum Donauwörth, Donauwörth, Germany

6. Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

7. Deutsche Konsortium für translationale Krebsforschung (DKTK) of the German Cancer Research Center (DKFZ), Heidelberg, Germany

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression;Advances in Biological Regulation;2024-01

2. Deregulation of Autophagy and Apoptosis in Patients with Myelodysplastic Syndromes: Implications for Disease Development and Progression;Current Issues in Molecular Biology;2023-05-08

3. The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes;International Journal of Molecular Sciences;2023-03-01

4. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation;Cell Reports Medicine;2023-02

5. The genetics of myelodysplastic syndromes and the opportunities for tailored treatments;Frontiers in Oncology;2022-10-20